Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TAREK MOURIS MEKHAIL

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1447214911
CMS profile
20341
Location
ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$298,562.48

231 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $90,257.96 54
E.R. Squibb & Sons, L.L.C. $75,840.99 44
Daiichi Sankyo Inc. $48,121.29 48
Amgen Inc. $30,505.43 31
Coherus Biosciences Inc. $11,924.51 10
Merck Sharp & Dohme LLC $11,555.27 13
Regeneron Healthcare Solutions, Inc. $11,171.74 15
Lilly USA, LLC $7,838.15 4
Eli Lilly and Company $4,950.00 2
Novocure Inc. $2,600.00 1
CATALYST PHARMACEUTICALS, INC. $2,349.69 2
Celltrion, Inc. $1,200.00 1
Gilead Sciences, Inc. $108.51 3
Incyte Corporation $99.95 1
Genentech USA, Inc. $38.99 2

Page 4 of 5; records 151–200 of 231 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TAREK MOURIS MEKHAIL

NPI 1447214911 · CMS profile ID 20341

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 231 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447214911?year=2024&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TAREK MOURIS MEKHAIL, NPI 1447214911, CMS profile ID 20341. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 231 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447214911?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). TAREK MOURIS MEKHAIL, NPI 1447214911, CMS profile ID 20341. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 231 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447214911?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
TAREK MOURIS MEKHAIL, NPI 1447214911, CMS profile ID 20341, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 231 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1447214911?year=2024&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

231 matching records · $298,562.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 231 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 231.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $375.0005/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104649027 CMS
Coherus Biosciences Inc. $1,350.0005/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147278046 CMS
Merck Sharp & Dohme LLC $1,223.0605/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141717356 CMS
Merck Sharp & Dohme LLC $1,442.5605/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141717532 CMS
Genentech USA, Inc. $19.7505/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133122232 CMS
AstraZeneca Pharmaceuticals LP $5,500.0004/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105801355 CMS
Daiichi Sankyo Inc. $139.4804/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089455988 CMS
Amgen Inc. $335.0004/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117627810 CMS
Amgen Inc. $7.0004/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117627812 CMS
Amgen Inc. $2,900.0004/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117627814 CMS
Amgen Inc. $483.0004/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117627816 CMS
Coherus Biosciences Inc. $694.2004/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147278030 CMS
Coherus Biosciences Inc. $367.3204/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147278032 CMS
Coherus Biosciences Inc. $39.4004/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147278034 CMS
Coherus Biosciences Inc. $374.7904/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147278036 CMS
Coherus Biosciences Inc. $24.0004/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147278038 CMS
Coherus Biosciences Inc. $7,425.0004/18/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147278040 CMS
Coherus Biosciences Inc. $14.9804/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147278042 CMS
Coherus Biosciences Inc. $116.0704/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147278044 CMS
AstraZeneca Pharmaceuticals LP $241.2004/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104353894 CMS
AstraZeneca Pharmaceuticals LP $115.5604/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105737381 CMS
AstraZeneca Pharmaceuticals LP $1,350.0004/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104546018 CMS
Amgen Inc. $603.7504/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117627818 CMS
Daiichi Sankyo Inc. $150.1204/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089455930 CMS
Daiichi Sankyo Inc. $24.0004/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089455942 CMS
Daiichi Sankyo Inc. $26.8004/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089455956 CMS
Merck Sharp & Dohme LLC $4,270.0004/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141717346 CMS
Daiichi Sankyo Inc. $5,500.0004/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089455934 CMS
Merck Sharp & Dohme LLC $150.0004/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141717348 CMS
Daiichi Sankyo Inc. $480.4903/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089455928 CMS
Daiichi Sankyo Inc. $104.7803/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089455932 CMS
Daiichi Sankyo Inc. $955.5403/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089455950 CMS
E.R. Squibb & Sons, L.L.C. $6,352.0003/28/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101396102 CMS
Coherus Biosciences Inc. $1,518.7503/27/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147278028 CMS
Incyte Corporation $99.9503/19/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141270018 CMS
AstraZeneca Pharmaceuticals LP $5,500.0003/18/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105856870 CMS
E.R. Squibb & Sons, L.L.C. $9,528.0003/18/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101396098 CMS
Merck Sharp & Dohme LLC $64.9903/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141678497 CMS
Merck Sharp & Dohme LLC $59.9903/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141678501 CMS
Merck Sharp & Dohme LLC $49.4803/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141678521 CMS
Merck Sharp & Dohme LLC $54.9903/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141678597 CMS
Merck Sharp & Dohme LLC $119.0603/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141678499 CMS
Merck Sharp & Dohme LLC $760.9703/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141678503 CMS
Merck Sharp & Dohme LLC $161.1703/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141678595 CMS
Merck Sharp & Dohme LLC $149.0003/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141862162 CMS
E.R. Squibb & Sons, L.L.C. $720.1203/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101396100 CMS
E.R. Squibb & Sons, L.L.C. $54.6103/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101396082 CMS
E.R. Squibb & Sons, L.L.C. $26.8003/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101396088 CMS
E.R. Squibb & Sons, L.L.C. $48.0003/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101396090 CMS
E.R. Squibb & Sons, L.L.C. $8.0003/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101396092 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $336,575.02 244
PY2020 $150,833.01 111
PY2021 $270,088.32 215
PY2022 $369,943.54 293
PY2023 $446,281.44 316
PY2024 $298,562.48 231
PY2025 $368,479.09 238

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,768,828.32 247
PY2024 Principal investigator $1,170,325.71 109
PY2023 Principal investigator $1,396,237.27 80
PY2022 Principal investigator $1,923,901.07 96
PY2021 Recipient $1,270.00 2
PY2021 Principal investigator $1,557,403.99 90
PY2020 Recipient $600.00 1
PY2020 Principal investigator $747,855.68 78
PY2019 Recipient $4,912.54 1
PY2019 Principal investigator $441,978.21 53

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

247 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $269.30 12/31/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel,Nab-Paclitaxel Chemotherapy with or without Pembrolizumab MK-3475 in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects KEYNOTE-407 No dispute reported 06/30/2026 1232926003
Principal investigator 1 Merck Sharp & Dohme LLC $17,540.72 12/31/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC No dispute reported 06/30/2026 1232926843
Principal investigator 1 Merck Sharp & Dohme LLC $8,970.54 12/31/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metast No dispute reported 06/30/2026 1232927511
Principal investigator 1 Amgen Inc. $1,000.00 12/23/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Sotorasib (AMG 510) Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and Sotorasib (AMG 510) Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreaK 100) No dispute reported 06/30/2026 1246638010
Principal investigator 1 Janssen Research & Development, LLC $2,536.00 12/22/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175391787
Principal investigator 1 Aveo Pharmaceuticals, Inc. $952.00 12/19/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
Head And Neck Cancer Squamous Cell Carcinoma No dispute reported 06/30/2026 1199913191
Principal investigator 1 Daiichi Sankyo Inc. $81.84 12/17/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343861
Principal investigator 1 Daiichi Sankyo Inc. $2,181.00 12/15/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343677
Principal investigator 1 Janssen Research & Development, LLC $3,155.00 12/15/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175391731
Principal investigator 1 Daiichi Sankyo Inc. $476.00 12/10/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343837
Principal investigator 1 Amgen Inc. $103.04 12/08/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH INSTITUTE
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309) No dispute reported 06/30/2026 1246649902
Principal investigator 1 Aveo Pharmaceuticals, Inc. $8,671.31 12/08/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
Head And Neck Cancer Squamous Cell Carcinoma No dispute reported 06/30/2026 1199913185
Principal investigator 1 PFIZER INC. $4,401.00 12/06/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600EK MUTATIONPOSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA No dispute reported 06/30/2026 1228746792
Principal investigator 1 Daiichi Sankyo Inc. $5,465.00 12/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343855
Principal investigator 1 Daiichi Sankyo Inc. $31.00 12/01/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343847
Principal investigator 1 Daiichi Sankyo Inc. $41.70 12/01/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343851
Principal investigator 1 Daiichi Sankyo Inc. $31.00 12/01/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343857
Principal investigator 1 Genmab U.S., Inc. $11,272.50 11/20/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921632
Principal investigator 1 Genmab U.S., Inc. $360.45 11/20/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921644
Principal investigator 1 Janssen Research & Development, LLC $257.00 11/20/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175391386
Principal investigator 1 Daiichi Sankyo Inc. $476.00 11/19/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343679
Principal investigator 1 Daiichi Sankyo Inc. $3,117.00 11/19/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343681
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,195.06 11/18/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
Head And Neck Cancer Squamous Cell Carcinoma No dispute reported 06/30/2026 1199913187
Principal investigator 1 Genmab U.S., Inc. $476.00 11/13/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921635
Principal investigator 1 Genmab U.S., Inc. $476.00 11/13/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921639
Principal investigator 1 Janssen Research & Development, LLC $5,530.00 11/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175391640
Principal investigator 1 Daiichi Sankyo Inc. $4,955.00 11/05/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343841
Principal investigator 1 Daiichi Sankyo Inc. $8,924.00 11/05/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343843
Principal investigator 1 Daiichi Sankyo Inc. $6,102.00 11/05/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343849
Principal investigator 1 Daiichi Sankyo Inc. $2,145.00 11/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343667
Principal investigator 1 Daiichi Sankyo Inc. $936.00 11/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343669
Principal investigator 1 Daiichi Sankyo Inc. $3,117.00 11/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343673
Principal investigator 1 Daiichi Sankyo Inc. $3,117.00 11/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343685
Principal investigator 1 Daiichi Sankyo Inc. $476.00 10/28/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343853
Principal investigator 1 Janssen Research & Development, LLC $1,485.00 10/23/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175391781
Principal investigator 1 Aveo Pharmaceuticals, Inc. $476.00 10/20/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
Head And Neck Cancer Squamous Cell Carcinoma No dispute reported 06/30/2026 1199913189
Principal investigator 1 Daiichi Sankyo Inc. $31.00 10/13/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343663
Principal investigator 1 Daiichi Sankyo Inc. $31.00 10/13/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343665
Principal investigator 1 Daiichi Sankyo Inc. $36.50 10/13/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343671
Principal investigator 1 Daiichi Sankyo Inc. $15.50 10/13/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343675
Principal investigator 1 Daiichi Sankyo Inc. $46.50 10/13/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343683
Principal investigator 1 Daiichi Sankyo Inc. $93.00 10/13/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343687
Principal investigator 1 Daiichi Sankyo Inc. $74.70 10/13/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343689
Principal investigator 1 Daiichi Sankyo Inc. $31.00 10/13/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343691
Principal investigator 1 Janssen Research & Development, LLC $210.00 10/13/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175391551
Principal investigator 1 Genmab U.S., Inc. $3,622.66 10/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921620
Principal investigator 1 Genmab U.S., Inc. $12,070.56 10/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921624
Principal investigator 1 Genmab U.S., Inc. $476.00 10/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921628
Principal investigator 1 Daiichi Sankyo Inc. $476.00 10/08/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343839
Principal investigator 1 Daiichi Sankyo Inc. $600.00 10/08/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343845
Principal investigator 1 Aveo Pharmaceuticals, Inc. $11,248.17 10/06/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
Head And Neck Cancer Squamous Cell Carcinoma No dispute reported 06/30/2026 1199913183
Principal investigator 1 Daiichi Sankyo Inc. $1,015.00 10/06/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343831
Principal investigator 1 Daiichi Sankyo Inc. $1,258.00 10/06/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343835
Principal investigator 1 Daiichi Sankyo Inc. $6,210.00 10/06/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343859
Principal investigator 1 Daiichi Sankyo Inc. $31.00 10/01/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343829
Principal investigator 1 Daiichi Sankyo Inc. $4.40 10/01/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343833
Principal investigator 1 Janssen Research & Development, LLC $502.00 09/29/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175391400
Principal investigator 1 Janssen Research & Development, LLC $5,098.00 09/22/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175391370
Principal investigator 1 Janssen Research & Development, LLC $1,485.00 09/22/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175391376
Principal investigator 1 Daiichi Sankyo Inc. $3,117.00 09/17/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343597
Principal investigator 1 Daiichi Sankyo Inc. $2,817.00 09/17/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343599
Principal investigator 1 Daiichi Sankyo Inc. $1,742.00 09/17/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343601
Principal investigator 1 Daiichi Sankyo Inc. $3,499.00 09/17/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343603
Principal investigator 1 Daiichi Sankyo Inc. $4,612.00 09/17/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343605
Principal investigator 1 Daiichi Sankyo Inc. $5,426.00 09/17/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343623
Principal investigator 1 Daiichi Sankyo Inc. $3,714.00 09/17/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343625
Principal investigator 1 Daiichi Sankyo Inc. $2,817.00 09/17/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343627
Principal investigator 1 Daiichi Sankyo Inc. $5,426.00 09/17/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343629
Principal investigator 1 PFIZER INC. $250.00 09/13/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600EK MUTATIONPOSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA No dispute reported 06/30/2026 1228760049
Principal investigator 1 Daiichi Sankyo Inc. $600.00 09/12/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343607
Principal investigator 1 Janssen Research & Development, LLC $600.00 09/12/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175391592
Principal investigator 1 Daiichi Sankyo Inc. $1,258.00 09/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343815
Principal investigator 1 Daiichi Sankyo Inc. $7,100.00 09/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343817
Principal investigator 1 Daiichi Sankyo Inc. $1,258.00 09/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343819
Principal investigator 1 Daiichi Sankyo Inc. $2,322.00 09/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343821
Principal investigator 1 Daiichi Sankyo Inc. $6,440.00 09/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343823
Principal investigator 1 Daiichi Sankyo Inc. $1,258.00 09/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343825
Principal investigator 1 Aveo Pharmaceuticals, Inc. $6,729.27 09/08/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199913169
Principal investigator 1 Janssen Research & Development, LLC $5,827.00 09/01/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175391658
Principal investigator 1 Genmab U.S., Inc. $10,867.98 08/27/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921585
Principal investigator 1 Genmab U.S., Inc. $6,702.75 08/27/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921600
Principal investigator 1 Janssen Research & Development, LLC $1,485.00 08/20/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175391509
Principal investigator 1 Genmab U.S., Inc. $476.00 08/19/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921573
Principal investigator 1 Genmab U.S., Inc. $4,969.35 08/19/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921582
Principal investigator 1 Genmab U.S., Inc. $1,676.00 08/19/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921596
Principal investigator 1 Genmab U.S., Inc. $17,505.45 08/13/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921604
Principal investigator 1 PFIZER INC. $4,401.00 08/13/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600EK MUTATIONPOSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA No dispute reported 06/30/2026 1228788773
Principal investigator 1 Daiichi Sankyo Inc. $31.00 08/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343577
Principal investigator 1 Daiichi Sankyo Inc. $31.00 08/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343631
Principal investigator 1 Daiichi Sankyo Inc. $31.00 08/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343633
Principal investigator 1 Daiichi Sankyo Inc. $31.00 08/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343635
Principal investigator 1 Daiichi Sankyo Inc. $31.00 08/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343637
Principal investigator 1 Daiichi Sankyo Inc. $31.00 08/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343639
Principal investigator 1 Daiichi Sankyo Inc. $31.00 08/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343641
Principal investigator 1 Daiichi Sankyo Inc. $31.00 08/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343643
Principal investigator 1 Daiichi Sankyo Inc. $31.00 08/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343645
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343647
Principal investigator 1 Daiichi Sankyo Inc. $31.00 08/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343649
Principal investigator 1 Daiichi Sankyo Inc. $31.00 08/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343651
Principal investigator 1 Daiichi Sankyo Inc. $62.00 08/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343653
Principal investigator 1 Daiichi Sankyo Inc. $31.00 08/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343655
Principal investigator 1 Genmab U.S., Inc. $8,915.40 08/06/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921616
Principal investigator 1 Aveo Pharmaceuticals, Inc. $12,222.21 08/05/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199913167
Principal investigator 1 Daiichi Sankyo Inc. $37.35 08/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343781
Principal investigator 1 Daiichi Sankyo Inc. $83.40 08/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343783
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343785
Principal investigator 1 Daiichi Sankyo Inc. $618.60 08/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343787
Principal investigator 1 Daiichi Sankyo Inc. $37.35 08/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343789
Principal investigator 1 Daiichi Sankyo Inc. $37.35 08/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343791
Principal investigator 1 Daiichi Sankyo Inc. $54.75 08/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343793
Principal investigator 1 Daiichi Sankyo Inc. $15.50 08/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343795
Principal investigator 1 Daiichi Sankyo Inc. $31.00 08/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343797
Principal investigator 1 Daiichi Sankyo Inc. $31.00 08/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343799
Principal investigator 1 Daiichi Sankyo Inc. $31.00 08/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343801
Principal investigator 1 Daiichi Sankyo Inc. $62.00 08/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343803
Principal investigator 1 Daiichi Sankyo Inc. $5,932.00 08/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343805
Principal investigator 1 Daiichi Sankyo Inc. $1,258.00 08/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343807
Principal investigator 1 Daiichi Sankyo Inc. $1,258.00 08/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343809
Principal investigator 1 Daiichi Sankyo Inc. $6,118.00 08/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343811
Principal investigator 1 Daiichi Sankyo Inc. $2,282.00 08/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343813
Principal investigator 1 Daiichi Sankyo Inc. $41.70 08/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343827
Principal investigator 1 Genmab U.S., Inc. $476.00 08/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921592
Principal investigator 1 Genmab U.S., Inc. $4,702.20 08/04/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921608
Principal investigator 1 Genmab U.S., Inc. $708.75 07/29/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921589
Principal investigator 1 Amgen Inc. $378,576.80 07/28/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309) No dispute reported 06/30/2026 1246638016
Principal investigator 1 Janssen Research & Development, LLC $2,840.00 07/28/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175391452
Principal investigator 1 Genmab U.S., Inc. $22,545.00 07/25/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921577
Principal investigator 1 Genmab U.S., Inc. $959.37 07/25/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921612
Principal investigator 1 Janssen Research & Development, LLC $1,670.00 07/24/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175391634
Principal investigator 1 Aveo Pharmaceuticals, Inc. $476.00 07/14/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199913165
Principal investigator 1 Daiichi Sankyo Inc. $46.50 07/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343573
Principal investigator 1 Daiichi Sankyo Inc. $46.50 07/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343575
Principal investigator 1 Daiichi Sankyo Inc. $91.25 07/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343593
Principal investigator 1 Daiichi Sankyo Inc. $86.30 07/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343595
Principal investigator 1 Daiichi Sankyo Inc. $46.50 07/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343609
Principal investigator 1 Daiichi Sankyo Inc. $46.50 07/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343611
Principal investigator 1 Daiichi Sankyo Inc. $62.55 07/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343613
Principal investigator 1 Daiichi Sankyo Inc. $46.50 07/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343615
Principal investigator 1 Daiichi Sankyo Inc. $46.50 07/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343617
Principal investigator 1 Daiichi Sankyo Inc. $46.50 07/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343619
Principal investigator 1 Daiichi Sankyo Inc. $20.85 07/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343621
Principal investigator 1 Daiichi Sankyo Inc. $46.50 07/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343657
Principal investigator 1 Daiichi Sankyo Inc. $37.35 07/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343659
Principal investigator 1 Daiichi Sankyo Inc. $46.50 07/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343661
Principal investigator 1 Daiichi Sankyo Inc. $1,329.00 07/02/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343579
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 07/02/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343581
Principal investigator 1 Daiichi Sankyo Inc. $750.00 07/02/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343583
Principal investigator 1 Daiichi Sankyo Inc. $4,500.00 07/02/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343585
Principal investigator 1 Daiichi Sankyo Inc. $22,700.00 07/02/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343587
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 07/02/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343589
Principal investigator 1 Daiichi Sankyo Inc. $1,000.00 07/02/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-188 No dispute reported 06/30/2026 1223343591
Principal investigator 1 Janssen Research & Development, LLC $2,433.00 07/01/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175391726
Principal investigator 1 Genmab U.S., Inc. $830.25 06/24/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921570
Principal investigator 1 Janssen Research & Development, LLC $252.00 06/23/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175391499
Principal investigator 1 Janssen Research & Development, LLC $1,485.00 06/23/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175391580
Principal investigator 1 Genmab U.S., Inc. $476.00 06/19/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921559
Principal investigator 1 Genmab U.S., Inc. $32,603.94 06/19/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921562
Principal investigator 1 Aveo Pharmaceuticals, Inc. $13,841.00 06/18/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199913175
Principal investigator 1 Janssen Research & Development, LLC $29,129.00 06/16/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175391770
Principal investigator 1 PFIZER INC. $4,651.00 06/13/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600EK MUTATIONPOSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA No dispute reported 06/30/2026 1228776706
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $72.90 06/13/2025 Covered Recipient Teaching Hospital
ADVENTHEALTH ORLANDO
A PHASE 1/2 STUDY OF THE SAFETY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF THE ORAL EGFR/HER2 INHIBITOR TAK-788 (AP32788) IN NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1223263394
Principal investigator 1 Daiichi Sankyo Inc. $1,000.00 06/02/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343771
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 06/02/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343773
Principal investigator 1 Daiichi Sankyo Inc. $4,500.00 06/02/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343775
Principal investigator 1 Daiichi Sankyo Inc. $1,329.00 06/02/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343777
Principal investigator 1 Daiichi Sankyo Inc. $1,300.00 06/02/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343779
Principal investigator 1 Janssen Research & Development, LLC $2,900.00 05/30/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175391394
Principal investigator 1 Janssen Research & Development, LLC $1,485.00 05/22/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175391765
Principal investigator 1 PFIZER INC. $1,766.00 05/22/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600EK MUTATIONPOSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA No dispute reported 06/30/2026 1228782675
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,576.00 05/20/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199913177
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,195.06 05/12/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199913173
Principal investigator 1 Genmab U.S., Inc. $8,888.40 05/08/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921566
Principal investigator 1 Janssen Research & Development, LLC $5,563.00 05/08/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175391598
Principal investigator 1 Janssen Research & Development, LLC $420.00 04/28/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175391539
Principal investigator 1 Mirati Therapeutics, Inc. $3,549.20 04/28/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Ther No dispute reported 06/30/2026 1236530168
Principal investigator 1 PFIZER INC. $673.65 04/26/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600EK MUTATIONPOSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA No dispute reported 06/30/2026 1228780270
Principal investigator 1 Janssen Research & Development, LLC $1,485.00 04/18/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175391574
Principal investigator 1 Genmab U.S., Inc. $2,082.71 04/17/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921554
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,676.00 04/16/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199913179
Principal investigator 1 PFIZER INC. $4,401.00 04/15/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600EK MUTATIONPOSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA No dispute reported 06/30/2026 1228797258
Principal investigator 1 Aveo Pharmaceuticals, Inc. $638.68 04/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199913171
Principal investigator 1 Aveo Pharmaceuticals, Inc. $476.00 04/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199913181
Principal investigator 1 Merck Sharp & Dohme LLC $6,907.00 04/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3, randomized, double-blind trial of pembrolizumab MK-3475 with or without lenvatinib E7080,MK-7902 in participants with treatment-na ve, metastatic nonsmall cell lung cancer NSCLC whose tumors have a tumor proportion score TPS greater tha No dispute reported 06/30/2026 1232936786
Principal investigator 1 Amgen Inc. $5,276.00 04/07/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Double-blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO (Nivolumab) in Resected Stage III or Stage IV Melanoma Subjects in the Adjuvant Setting No dispute reported 06/30/2026 1246638024
Principal investigator 1 Genmab U.S., Inc. $476.00 03/20/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921534
Principal investigator 1 Genmab U.S., Inc. $179,670.98 03/20/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921543
Principal investigator 1 Janssen Research & Development, LLC $3,155.00 03/20/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175391481
Principal investigator 1 Aveo Pharmaceuticals, Inc. $6,425.33 03/18/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199913159
Principal investigator 1 Aveo Pharmaceuticals, Inc. $9,845.13 03/18/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199913161
Principal investigator 1 Daiichi Sankyo Inc. $22,700.00 03/14/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343863
Principal investigator 1 PFIZER INC. $438.75 03/13/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600EK MUTATIONPOSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA No dispute reported 06/30/2026 1228788643
Principal investigator 1 Genmab U.S., Inc. $476.00 03/06/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921550
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343693
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343695
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343697
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343699
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343701
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343703
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343705
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343707
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343709
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343711
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343713
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343715
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343717
Principal investigator 1 Daiichi Sankyo Inc. $4.25 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343719
Principal investigator 1 Daiichi Sankyo Inc. $44.70 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343721
Principal investigator 1 Daiichi Sankyo Inc. $112.05 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343723
Principal investigator 1 Daiichi Sankyo Inc. $112.05 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343725
Principal investigator 1 Daiichi Sankyo Inc. $62.55 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343727
Principal investigator 1 Daiichi Sankyo Inc. $29.25 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343729
Principal investigator 1 Daiichi Sankyo Inc. $15.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343731
Principal investigator 1 Daiichi Sankyo Inc. $15.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343733
Principal investigator 1 Daiichi Sankyo Inc. $15.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343735
Principal investigator 1 Daiichi Sankyo Inc. $15.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343737
Principal investigator 1 Daiichi Sankyo Inc. $154.65 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343739
Principal investigator 1 Daiichi Sankyo Inc. $62.55 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343741
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343743
Principal investigator 1 Daiichi Sankyo Inc. $86.30 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343745
Principal investigator 1 Daiichi Sankyo Inc. $15.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343747
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343749
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343751
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343753
Principal investigator 1 Daiichi Sankyo Inc. $20.85 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343755
Principal investigator 1 Daiichi Sankyo Inc. $48.35 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343757
Principal investigator 1 Daiichi Sankyo Inc. $37.35 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343759
Principal investigator 1 Daiichi Sankyo Inc. $46.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343761
Principal investigator 1 Daiichi Sankyo Inc. $50.15 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343763
Principal investigator 1 Daiichi Sankyo Inc. $255.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343765
Principal investigator 1 Daiichi Sankyo Inc. $17.60 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343767
Principal investigator 1 Daiichi Sankyo Inc. $15.50 03/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
DS7300-189 No dispute reported 06/30/2026 1223343769
Principal investigator 1 Merck Sharp & Dohme LLC $10,047.16 02/24/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metast No dispute reported 06/30/2026 1232927341
Principal investigator 1 Genmab U.S., Inc. $360.45 02/20/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921539
Principal investigator 1 Janssen Research & Development, LLC $1,670.00 02/20/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175391471
Principal investigator 1 Genentech, Inc. $2,134.30 02/14/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
My Pathway No dispute reported 06/30/2026 1211539649
Principal investigator 1 PFIZER INC. $517.05 02/13/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600EK MUTATIONPOSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA No dispute reported 06/30/2026 1228750011
Principal investigator 1 Aveo Pharmaceuticals, Inc. $18,090.00 02/11/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199913163
Principal investigator 1 Aveo Pharmaceuticals, Inc. $10,354.91 02/03/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) No dispute reported 06/30/2026 1199913157
Principal investigator 1 Janssen Research & Development, LLC $210.00 01/30/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175391418
Principal investigator 1 AstraZeneca Pharmaceuticals LP $129,309.36 01/22/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab MEDI4736 and domvanalimab AB154 compared with durvalumab plus placebo in adults with locally advanced Stage III No dispute reported 06/30/2026 1185549287
Principal investigator 1 Janssen Research & Development, LLC $1,485.00 01/20/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175391653
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,665.72 01/15/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) No dispute reported 06/30/2026 1185549285
Principal investigator 1 AstraZeneca UK Limited $27,993.96 01/15/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase III,Open label,Randomised,Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations,and Whose Disease Has Progressed On or After Prior Anti PD 1 Therapy and Platinum based Chemotherapy LATIFY No dispute reported 06/30/2026 1185549293
Principal investigator 1 AstraZeneca UK Limited $28,414.85 01/14/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON) No dispute reported 06/30/2026 1185549289
Principal investigator 1 Genmab U.S., Inc. $476.00 01/09/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1235921546
Principal investigator 1 AstraZeneca Pharmaceuticals LP $363,268.25 01/08/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton No dispute reported 06/30/2026 1185549291
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $13,611.40 01/06/2025 Covered Recipient Teaching Hospital
Adventhealth Orlando
A Phase 3, Randomized, Open-Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC) No dispute reported 06/30/2026 1236001869